State Street’s Nektar Therapeutics NKTR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$17.6M Buy
244,727
+49,071
+25% +$2.79M ﹤0.01% 2303
2025
Q4
$8.27M Buy
195,656
+66,657
+52% +$3.73M ﹤0.01% 2739
2025
Q3
$7.34M Buy
128,999
+78,894
+157% +$2.61M ﹤0.01% 2809
2025
Q2
$1.29M Sell
50,105
-167,114
-77% -$1.88M ﹤0.01% 3437
2025
Q1
$2.22M Sell
217,219
-921
-0.4% -$12K ﹤0.01% 3205
2024
Q4
$3.04M Sell
218,140
-4,909
-2% -$86.6K ﹤0.01% 3172
2024
Q3
$4.35M Buy
223,049
+23,717
+12% +$452K ﹤0.01% 3028
2024
Q2
$3.71M Buy
199,332
+153,210
+332% +$3.23M ﹤0.01% 3057
2024
Q1
$646K Sell
46,122
-1,620
-3% -$17K ﹤0.01% 3581
2023
Q4
$405K Hold
47,742
﹤0.01% 3692
2023
Q3
$427K Sell
47,742
-654
-1% -$6.3K ﹤0.01% 3710
2023
Q2
$418K Sell
48,396
-417,010
-90% -$4.45M ﹤0.01% 3737
2023
Q1
$4.91M Sell
465,406
-23,633
-5% -$715K ﹤0.01% 2998
2022
Q4
$16.6M Sell
489,039
-34,754
-7% -$1.68M ﹤0.01% 2375
2022
Q3
$25.1M Sell
523,793
-58,138
-10% -$3.46M ﹤0.01% 2053
2022
Q2
$33.2M Buy
581,931
+195,244
+50% +$12.3M ﹤0.01% 1900
2022
Q1
$31.3M Buy
386,687
+33,917
+10% +$5.02M ﹤0.01% 2072
2021
Q4
$71.5M Buy
352,770
+42,829
+14% +$9.29M ﹤0.01% 1555
2021
Q3
$83.5M Sell
309,941
-6,564
-2% -$1.58M ﹤0.01% 1420
2021
Q2
$81.5M Buy
316,505
+24,599
+8% +$6.81M ﹤0.01% 1463
2021
Q1
$87.6M Sell
291,906
-6,466
-2% -$2.01M 0.01% 1329
2020
Q4
$76.1M Buy
298,372
+15,031
+5% +$3.88M ﹤0.01% 1366
2020
Q3
$70.5M Sell
283,341
-14,302
-5% -$4.5M ﹤0.01% 1199
2020
Q2
$103M Sell
297,643
-11,127
-4% -$3.47M 0.01% 933
2020
Q1
$82.7M Buy
308,770
+5,430
+2% +$1.68M 0.01% 949
2019
Q4
$98.2M Sell
303,340
-191,293
-39% -$55.5M 0.01% 1068
2019
Q3
$135M Buy
494,633
+18,466
+4% +$6.77M 0.01% 834
2019
Q2
$254M Buy
476,167
+2,907
+0.6% +$1.46M 0.02% 630
2019
Q1
$239M Buy
473,260
+20,565
+5% +$12.2M 0.02% 627
2018
Q4
$223M Buy
452,695
+11,860
+3% +$7.16M 0.02% 599
2018
Q3
$403M Buy
440,835
+40,574
+10% +$34.6M 0.03% 484
2018
Q2
$293M Sell
400,261
-21,513
-5% -$24.8M 0.02% 557
2018
Q1
$672M Buy
421,774
+156,520
+59% +$202M 0.06% 325
2017
Q4
$238M Buy
265,254
+692
+0.3% +$409K 0.02% 625
2017
Q3
$95.2M Sell
264,562
-29,323
-10% -$9.17M 0.01% 1006
2017
Q2
$86.2M Buy
293,885
+29,802
+11% +$8.61M 0.01% 1034
2017
Q1
$93M Sell
264,083
-6,748
-2% -$1.52M 0.01% 985
2016
Q4
$49.8M Buy
270,831
+48,722
+22% +$9.91M ﹤0.01% 1268
2016
Q3
$57.2M Buy
222,109
+4,077
+2% +$1.05M 0.01% 1152
2016
Q2
$46.5M Sell
218,032
-13,976
-6% -$3.12M 0.01% 1220
2016
Q1
$47.9M Buy
232,008
+10,091
+5% +$1.94M 0.01% 1192
2015
Q4
$56.1M Sell
221,917
-92,683
-29% -$19.1M 0.01% 1118
2015
Q3
$51.7M Sell
314,600
-45,945
-13% -$8.13M 0.01% 1146
2015
Q2
$67.7M Buy
360,545
+39,927
+12% +$6.87M 0.01% 1082
2015
Q1
$52.9M Buy
320,618
+46,034
+17% +$9.46M 0.01% 1202
2014
Q4
$63.8M Sell
274,584
-2,963
-1% -$633K 0.01% 1091
2014
Q3
$50.2M Sell
277,547
-34,547
-11% -$6.61M 0.01% 1181
2014
Q2
$60M Buy
312,094
+32,532
+12% +$5.75M 0.01% 1137
2014
Q1
$50.8M Sell
279,562
-7,480
-3% -$1.48M 0.01% 1186
2013
Q4
$48.9M Buy
287,042
+62,923
+28% +$10.1M 0.01% 1205
2013
Q3
$35.1M Buy
224,119
+19,836
+10% +$3.67M ﹤0.01% 1350
2013
Q2
$35.4M Buy
+204,283
New +$31.3M ﹤0.01% 1301

Other funds holding NKTR

State Street's NKTR Position: Q1 2026 in Review

State Street increased its Nektar Therapeutics (NKTR) stake by 25% in Q1 2026, buying an estimated $2.79M and bringing the position to 244,727 shares worth $17.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2303.

State Street first reported a position in NKTR in Q2 2013 and has held it in 52 quarters since. The position peaked at $672M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • State Street held 244,727 shares of Nektar Therapeutics worth $17.6M as of Q1 2026.
  • State Street bought 49,071 Nektar Therapeutics shares in Q1 2026, an estimated $2.79M.
  • Nektar Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #2303 holding.
  • State Street first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • State Street's Nektar Therapeutics position peaked at $672M in Q1 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.